Annual report pursuant to Section 13 and 15(d)

Segment Reporting (Tables)

v3.22.2.2
Segment Reporting (Tables)
12 Months Ended
Jun. 30, 2022
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment

    

Biopharmaceuticals

    

Bioprocessing

    

    

Year Ended June 30, 2022 (in thousands)

    

iBio, Inc.

    

iBio CDMO

    

Eliminations

    

Total

Revenues - external customers

$

1,884

$

499

$

$

2,383

Revenues - intersegment

1,586

2,455

(4,041)

Cost of goods sold

216

216

Gross profit

3,470

2,739

(4,041)

2,167

Research and development

 

11,819

8,260

(2,350)

 

17,729

General and administrative

 

20,844

14,975

(1,691)

 

34,128

Operating loss

 

(29,194)

(20,496)

 

(49,690)

Interest expense

 

(1,412)

 

(1,412)

Forgiveness of note payable and accrued interest

607

607

Interest and other income

 

184

7

 

191

Consolidated net loss

 

(29,010)

(21,295)

 

(50,305)

Total assets

 

156,893

43,092

(100,578)

 

99,407

Finance lease ROU assets

 

74

 

74

Operating lease ROU assets

3,068

1,952

5,020

Fixed assets, net of accumulated depreciation

1,373

35,288

36,661

Intangible assets, net of accumulated amortization

 

4,851

 

 

 

4,851

Amortization of ROU assets

 

 

599

 

 

599

Depreciation expense

 

 

2,275

 

 

2,275

Amortization of intangible assets

401

401

    

Biopharmaceuticals

Bioprocessing

Year Ended June 30, 2021 (in thousands)

    

iBio, Inc.

iBio CDMO

Eliminations

Total

Revenues - external customers

$

1,098

$

1,274

$

$

2,371

Revenues - intersegment

1,017

1,307

(2,324)

Cost of goods sold

425

1,037

1,462

Gross profit

1,690

1,543

(2,324)

909

Research and development

 

2,960

 

8,370

 

(1,341)

 

9,989

General and administrative

 

13,429

 

9,585

 

(983)

 

22,031

Operating loss

 

(14,699)

 

(16,412)

 

 

(31,111)

Interest expense

 

 

(2,454)

 

 

(2,454)

Settlement income

10,200

10,200

Interest and royalty income

 

151

 

1

 

 

152

Consolidated net loss

 

(4,349)

 

(18,864)

 

 

(23,213)

Total assets

 

175,272

 

35,721

 

(64,025)

 

146,968

Finance lease ROU assets

 

 

26,111

 

 

26,111

Fixed assets, net of accumulated depreciation

8,628

8,628

Intangible assets, net of accumulated amortization

952

952

Amortization of finance lease ROU assets

 

 

1,651

 

 

1,651

Depreciation expense

 

 

472

 

 

472

Amortization of intangible assets

 

291

 

 

 

291